ArticleThe Prostate2020
Validation of a prostate cancer polygenic risk score.
Article in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.Nature communications · 2023Pooled it
- RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.International journal of cancer · 2026Article
- Clinical translation of polygenic scores for prostate cancer screening.Nature reviews. Urology · 2026Review
- Does inclusion of neighborhood variables improve clinical risk prediction for advanced prostate cancer in Black and White men?Urologic oncology · 2025Article
- Clinical features of prostate cancer by polygenic risk score.Familial cancer · 2024Article
- Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa.Nature genetics · 2024Article
- Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese.Scientific reports · 2024Article
- The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance.World journal of urology · 2024Article
- Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa.Research square · 2023Article
- Clinical utility of polygenic risk scores: a critical 2023 appraisal.Journal of community genetics · 2023Article
- Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians.Scientific reports · 2023Article
- Early prediction of prostate cancer risk in younger men using polygenic risk scores and electronic health records.Cancer medicine · 2023Article
- The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study.Frontiers in oncology · 2023Article
- Race and prostate cancer: genomic landscape.Nature reviews. Urology · 2022Review
- Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.Prostate cancer and prostatic diseases · 2022Review
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG advances · 2022Article
- Article
- Design and user experience testing of a polygenic score report: a qualitative study of prospective users.BMC medical genomics · 2021Review
- Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review.Investigative and clinical urology · 2021Review
- Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.Cancers · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenome-wide association studies have identified over 100 single-nucleotide polymorphisms (SNPs) associated with prostate cancer (PrCa), and polygenic risk scores (PRS) based on their combined genotypes have been developed for risk stratification. We aimed to assess the contribution of PRS to PrCa risk in a large multisite study.
methodsThe sample included 1972 PrCa cases and 1919 unaffected controls. Next-generation sequencing was used to assess pathogenic variants in 14 PrCa-susceptibility genes and 72 validated PrCa-associated SNPs. We constructed a population-standardized PRS and tested its association with PrCa using logistic regression adjusted for age and family history of PrCa.
resultsThe mean age of PrCa cases at diagnosis and age of controls at testing/last clinic visit was 59.5 ± 7.2 and 57.2 ± 13.0 years, respectively. Among 1740 cases with pathology data, 57.4% had Gleason score ≤ 6, while 42.6% had Gleason score ≥ 8. In addition, 39.6% cases and 20.1% controls had a family history of PrCa. The PRS was significantly higher in cases than controls (mean ± SD: 1.42 ± 1.11 vs 1.02 ± 0.76; P < .0001). Compared with men in the 1st quartile of age-adjusted PRS, those in the 2nd, 3rd, and 4th quartile were 1.58 (95% confidence interval [CI]: 1.31-1.90), 2.36 (95% CI: 1.96-2.84), and 3.98 (95% CI: 3.29-4.82) times as likely to have PrCa (all P < .0001). Adjustment for family history yielded similar results. PRS predictive performance was consistent with prior literature (area under the receiver operating curve = 0.64; 95% CI: 0.62-0.66).
conclusionsThese data suggest that a 72-SNP PRS is predictive of PrCa, supporting its potential use in clinical risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.